AMCP Partnership Forum Develops Innovative Strategies that Support the Use and Development of Biosimilars in the US Health Care System
![](https://pharmashots.com/wp-content/uploads/2020/10/Press-Release.png)
-
Build positive, evidence-based communication and educational materials?around biosimilar adoption, differentiated to meet various audiences, including patients, prescribers/providers, and payers.?Amplify?existing resources, such as IQVIA data and FDA?education resources,?that help clarify some of the complexities around biosimilars.
-
Draw from best practices to clarify and simplify language?around biosimilars, particularly around the concepts of interchangeability and substitutability, as well as implement common language to increase confidence in switching.
-
Identify gaps in data?that may require development of new resources and surveillance mechanisms for biosimilar use. Collect?RWE and post-marketing surveillance?data?related to adverse events and side effects,?as well as switching data (reference products to biosimilars; biosimilars to biosimilars) to help evaluate relative effectiveness and safety.
-
Review benefit design?to address complexities to identify improvements that enhance access to biologic drugs, especially as more come to market that will be covered under the pharmacy benefit. In addition, investigate how to change provider reimbursement incentives to support prescribing of the most cost-effective product.
-
Continue to combat attempts to unfairly delay competition?and to?mitigate other?issues that are keeping biosimilars from gaining traction in the market.?As the biosimilar marketplace grows, it is expected that more experience will help to spur more evidence around, and comfortability with, biosimilars.
-
Work to rebuild the public?s confidence in science and the FDA approval process?through education and positive messaging, particularly?as?it?pertains?to biosimilars.
-
Share learnings from across disease states, stakeholder groups, and the globe?with the goal to pull together and disseminate best practices from areas where biosimilar uptake efforts have succeeded.